Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines.
(2020) Seminars in cell & developmental biology — Vol. 98, p. 181-191 (2020)
Files
103Reviewanthracyclines.pdf
Open Access - Adobe PDF
- 1.83 MB
Details
- Authors
De Miranda Capeloa, Tania Isabel 
- Abstract
- Anthracyclines Doxorubicin, Epirubicin, Daunorubicin and Idarubicin are used to treat a variety of tumor types in the clinics, either alone or, most often, in combination therapies. While their cardiotoxicity is well known, the emergence of chemoresistance is also a major issue accounting for treatment discontinuation. Resistance to anthracyclines is associated to the acquisition of multidrug resistance conferred by overexpression of permeability glycoprotein-1 or other efflux pumps, by altered DNA repair, changes in topoisomerase II activity, cancer stemness and metabolic adaptations. This review further details the metabolic aspects of resistance to anthracyclines, emphasizing the contributions of glycolysis, the pentose phosphate pathway and nucleotide biosynthesis, glutathione, lipid metabolism and autophagy to the chemoresistant phenotype.
- Affiliations
Citations
De Miranda Capeloa, T. I., Benyahia, Z., Zampieri, L., Blackman, M., & Sonveaux, P. (2020). Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. Seminars in cell & developmental biology, 98, 181-191. https://doi.org/10.1016/j.semcdb.2019.05.006 (Original work published 2020)